Your browser doesn't support javascript.
loading
Hemophagocytic lymphohistiocytosis/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study.
Patton, Laura; Monteith, Bethany; Heffernan, Paul; Herzinger, Thomas; Wilson, Brooke E.
Afiliación
  • Patton L; Department of Oncology, Queen's University, Kingston, ON, Canada.
  • Monteith B; Department of Haematology, Queen's University, Kingston, ON, Canada.
  • Heffernan P; Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
  • Herzinger T; Division of Dermatology, Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Wilson BE; Department of Oncology, Queen's University, Kingston, ON, Canada.
Front Oncol ; 14: 1394543, 2024.
Article en En | MEDLINE | ID: mdl-38919527
ABSTRACT
As indications for immune checkpoint inhibitors for breast cancer continue to expand, rare toxicities will emerge that require careful consideration and multidisciplinary management. We report the case of a 40-year-old female receiving neoadjuvant pembrolizumab and chemotherapy for locally advanced triple-negative breast cancer who developed cytokine release syndrome (CRS)/hemophagocytic lymphohistiocytosis (HLH). CRS/HLH secondary to pembrolizumab are scarcely documented in the literature and, to our knowledge, have never been reported in the context of neoadjuvant treatment for breast cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza